Amalgamated Financial’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Amalgamated Financial’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$155K	Buy	+5,765	New	+$194K	﹤0.01%	1993

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Amalgamated Financial's TPTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022: 5,765 shares worth $155K. The stake represents ﹤0.01% of the portfolio and ranks #1993 among its holdings.

155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

Amalgamated Financial held 5,765 shares of Turning Point Therapeutics, Inc. Common Stock worth $155K as of Q1 2022.
Turning Point Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Turning Point Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1993 holding.
155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.